Look Before You Leap: What the JAMA 2024 Video Laryngoscopy Trial Means for Your Airway Practice

Bougie-First Intubation: What 9,151 Patients Show [Journal Club]

For ten years I treated the bougie as a backup — the break-glass tool, Plan B. Then a 2024 systematic review and meta-analysis in Annals of Emergency Medicine made me reconsider whether it should be my first move on every airway. In this episode of Overheard Journal Club, I break down von Hellmann and colleagues’ pooled analysis of 18 studies and 9,151 patients: the headline 11% relative improvement in first-attempt success, the much larger benefit in difficult airways, and the honest caveats — high heterogeneity, low certainty, and a heavy dependence on operator skill. We also unpack the BEAM versus-BOUGIE plot twist that explains why the same tool can look transformative in one trial and useless in another, and I lay out a practical, four-step way to decide whether the bougie belongs in your hand on attempt number one. Key takeaways •  Across 18 studies and 9,151 patients, bougie use was associated with an 11% relative improvement in first-attempt success (RR 1.11). •  The benefit is much larger in difficult airways — Cormack-Lehane grade 3–4 — where the relative risk hit 1.60. •  Certainty is low and heterogeneity is high; the effectdepends heavily on who is holding the bougie. •  The bougie is a standard-geometry tool — keep direct laryngoscopy plus bougie fluent even if your department defaults to hyper-angulated video laryngoscopy. •  With a standard-geometry blade, consider moving the bougie from backup to first-line — then practice it. Disclaimer This podcast is for educational purposes only. It is not medical advice and does not establish a physician–patient relationship. Always discuss management decisions with a qualified clinician.

Look Before You Leap: What the JAMA 2024 Video Laryngoscopy Trial Means for Your Airway Practice

A device can win a randomized trial and still be the wrong tool for your environment. In this episode of Overheard Journal Club, Dr Cois takes apart the 2024 JAMA cluster-randomized trial comparing video and direct laryngoscopy across 8,429 operating-room procedures. Video laryngoscopy cut multiple intubation attempts from 7.6 per cent to 1.7 per cent and reduced device-switch failures roughly fifteen-fold, with no increase in airway or dental injury — a large, biologically plausible result. But the trial was single-center, mostly performed by trainees, and used a hyperangulated blade. Dr Cois explains why he agrees with the result for the OR, why he reaches for a standard-geometry blade in the emergency department, and how he keeps his direct laryngoscopy skills sharp for the day the camera fails. •  Video laryngoscopy reduced multiple intubation attemptsversus direct in the OR (1.7% vs 7.6%), with no rise in injury. •  Device-switch failure dropped roughly fifteen-fold with video. •  The trial used a hyperangulated blade — which commits you to a device swap if the camera is contaminated. •  In emergency airways, a standard-geometry blade lets you convert to direct without swapping devices. •  Preserve direct laryngoscopy skills: look down first on low-risk airways, convert to the screen when needed. Disclaimer: This content is for educational purposes only. Itdoes not constitute medical advice and does not establish a physician–patient relationship. Clinicians should rely on their own training, judgment, and local protocols; patients should discuss any management decisions with a qualified clinician.

The Fluoride-IQ Study, Read Properly [Journal Club]

In January 2025, a New York Times headline announced that fluoride exposure is linked to lower IQ in children. Within days, parents were tossing fluoride toothpaste and buying water filters, and a national political fight reignited over community water fluoridation. The paper behind the headline — Taylor et al, JAMA Pediatrics — is the largest and most rigorous meta-analysis of fluoride and children’s IQ ever assembled. It includes 74 studies and roughly 21,000 children. So it deserves a careful read, not a panicked one. And that’s what this episode is. Dr Cois, an Emergency Physician, breaks the paper down Journal Club style. He walks through the PICO framework — Population, Intervention, Comparator, Outcome — then steps through the three separate analyses inside the paper and explains why they don’t all point in the same direction. You’ll learn where the IQ signal is genuinely concerning (at high exposures), where it gets shaky (at the WHO threshold), and where it essentially disappears (at the levels an American kid actually drinks). You’ll also learn to spot cherry-picking — the influence tactic that takes a true finding, strips away its context, and turns it into a panic headline. And you’ll meet the more US relevant evidence the headlines ignored: the Australian Do et al cohort. Whether you’re a clinician fielding the “should I stop using fluoride?” question, a trainee learning to appraise a meta analysis, or a parent who just wants the truth — this one’s for you. Key takeaways •  The pooled IQ signal is driven largely by high-exposure, high risk-of-bias studies, and is largely absent below 1.5 mg/L in drinking water •  The best-quality data shows roughly one IQ point per 1 mg/L of urinary fluoride — negligible for an individual, debated at population scale •  The authors state plainly that this paper was not designed to address US water fluoridation •  Screen the patients who genuinely face high exposure — private wells, high-fluoride regions, pregnancy, and infancy — and leave the toothpaste alone Disclaimer This episode is for educational purposes only. It does not provide medical advice and does not establish a physician patient relationship. Always discuss management decisions with a qualified clinician. Full references are at DrCois.com.

Quick Hits: How an ED Doctor Reads a Medical Paper

Quick Hits Episode 6. A listener wrote in asking for a framework to read a medical paper — and it could not be timelier. Misinformation has now been ranked the most severe short-term risk facing the world by the World Economic Forum, ahead of armed conflict and cyber attacks. One in four Gen Z respondents turns to TikTok for medical advice, and viral medical content is consistently more likely to be wrong than non-viral content. In this episode, Dr Cois walks through the three-question framework that every medical student is taught — and that he still uses today on every paper he reads. Then he pressure-tests it by walking you through three different studies that have tried to answer the same question: does saturated fat raise your cardiovascular risk? A human-and-overfeeding mechanism study, an umbrella review of cohort data, and a Cochrane meta-analysis of randomised controlled trials — same question, three different weights of evidence, one converging answer. If you have ever wanted to push back on the loudest voice in the room without needing a medical degree, this is your playbook. Key Takeaways •  Misinformation is the #1 short-term global risk; thefirehose is not slowing down •  Three-question framework: study type and journal,funding and authors, PICO •  PICO unpacks to Population, Intervention, Comparator,and Outcome •  The body of evidence is what matters — convergenceacross study designs is the signal •  Five red flags: single studies, surrogate outcomes, relative risk without absolute risk, cherry-picking, and conclusions that don’t match the data •  Your homework: track one social-media health claim back to the paper and run the PICO Disclaimer This podcast is for educational purposes only and does not provide medical advice or establish a physician patient relationship. Always consult a qualified clinician for personal health questions.

Quick Hits | Why the Same Drug Can Cost $90 or $9 at the Same Pharmacy — A Doctor Explains

My pharmacy tried to charge me $90 for a generic nausea medication. Five minutes later, with a coupon I signed up for in the aisle, I paid $9. Same drug. Same store. Same five minutes. If that sounds impossible — or like a trick — this episode is for you. In Quick Hits Episode 5, I walk you through exactly how prescription drug pricing works in America, who is actually setting the price you pay (hint: not your insurance company, not the pharmacy), and the three-step habit you can use every single time you fill a script. This is one of those moments where a small amount of knowledge gives you real power. •  There is no single “real” price for your medication. Multiple negotiated prices exist, and which one you pay depends entirely on which contract you invoke at the counter. •  Pharmacy Benefit Managers (PBMs) — not your insurance company — do most of the actual price-setting. Three companies control 79% of all U.S. prescription drug claims. •  The “cash price” is almost never the real price. It’s a sticker price designed for patients who don’t know to ask for anything else • GoodRx isn’t cash. It’s a different PBM’s contract you can piggyback on. • Three habits, every prescription: Ask the cash price. Compare on GoodRx and Cost Plus Drugs. Choose the lowest legitimate option. •  The February 2026 PBM reforms are a real step forward — but none of it changes what you pay today. Disclaimer This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult your physician or pharmacist regarding your specific situation.